A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the ...

The company noted that no new safety concerns were identified with the combination of Imfinzi and BCG induction and ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ...

The facility, which will produce cell therapies used to treat cancer and auto immune diseases, creates 150 jobs for highly ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the ...

The facility to manufacture cell therapies for cancer research is part of the company's push to invest $3.5B in its U.S.

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

Cell therapy is considered by some as the next frontier in cancer treatment, engineering patients' own immune systems to ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) ...